
GLP-1 Drugs Linked to Fewer Asthma Attacks in Real-World Data
A UK real-world study finds GLP-1 receptor agonists such as semaglutide (Ozempic) linked to fewer asthma and COPD flare-ups versus sulfonylureas, with about a 40% drop in asthma attacks and a 20% drop in COPD flare-ups, but the findings are observational, not peer‑reviewed, and require clinical trials to establish causation.













